Biocartis
PrivateLast Round
Debt
Nov 22, 2023
Est. Valuation
$490.7M
Total Funding Raised
$344.48M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Biocartis operates in Healthcare & Life Sciences and is based in Mechelen. Its latest recorded funding round was a Debt round in November 2023.
Biocartis is a molecular diagnostics company that provides a fully automated, sample-to-result, real-time PCR platform for oncology and infectious disease testing.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment, Precision Medicine, Biotechnology
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biocartis Comparables
Compare Biocartis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hologic, Inc. | 79% | |
| Seegene Inc. | 77% | |
| Danaher | 74% |
For institutional investors. Book with your work email.
Biocartis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Nov 22, 2023 | ||||
| Recap | Nov 22, 2023 | ||||
| Private Placement | Nov 29, 2022 | ||||
| Private Placement | Jan 23, 2019 | ||||
| IPO | Apr 27, 2015 | ||||
Private Placement | Sep 4, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biocartis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UBS Group AG | IPO |
| Korys | Series C, Series D |
| KBC Group N.V. | Debt |
| Advent Venture Partners | Series A, Series B |
| KBC Securities | Private Placement |
| Aescap | Series B |
| PMV | Private Placement, Series C, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 44% MoM.
- Mar 24, 2026
Developing a rapid breast cancer gene signature test with Medical College of Wisconsin.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 30, 2026
Biocartis has an abstract on its Idylla(TM) Breast21 Assay accepted for poster presentation at the San Antonio Breast Cancer Symposium in Texas on Dec 8th-11th '26, where it presents initial development data.
For institutional investors. Book with your work email.
Biocartis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biocartis's valuation, stock price, and market status.
Is Biocartis a public or private company?
Biocartis is a private company.
What is the current stock price of Biocartis?
Biocartis is a private company, so its shares have no public market price. Caplight tracks Biocartis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biocartis worth (valuation)?
Biocartis's valuation is estimated at $490.7M based on funding round data.
Can I buy Biocartis stock?
Biocartis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biocartis's last funding round?
Biocartis's most recent funding round was Debt on November 22, 2023.
Who are the main investors in Biocartis?
Key investors in Biocartis include KBC Securities, Aescap, PMV, Aescap Venture.
Will Biocartis IPO soon?
No public IPO plans have been announced for Biocartis.
How can I track Biocartis secondary market activity?
Caplight tracks bids, offers, and trades in Biocartis's shares on secondary markets.